Authors: Gillian M Keating
Publish Date: 2013/07/10
Volume: 73, Issue: 11, Pages: 1227-1244
Abstract
The live attenuated shingles herpes zoster vaccine Zostavax® is approved in the EU for use in the prevention of herpes zoster and postherpetic neuralgia in adults aged ≥50 years In adults aged ≥60 years zoster vaccine reduced the burden of illness associated with herpes zoster with reductions in the incidence of postherpetic neuralgia and herpes zoster according to the results of the Shingles Prevention Study Results of subsequent Short and LongTerm Persistence Substudies indicate that the efficacy of zoster vaccine is maintained in the longer term albeit with a gradual decline over time In the Zostavax Efficacy and Safety Trial zoster vaccine reduced the incidence of herpes zoster in adults aged 50–59 years Findings of these studies are supported by the results of large retrospective cohort studies Zoster vaccine was generally well tolerated with injectionsite adverse events being the most commonly reported adverse events In conclusion zoster vaccine provides an important opportunity to reduce the burden of illness associated with herpes zoster by reducing the incidence of herpes zoster and postherpetic neuralgiaThe manuscript was reviewed by G Icardi Department of Health Sciences University of Genoa Genoa Italy C A Kauffman Division of Infectious Diseases Veterans Affairs Ann Arbor Healthcare System University of Michigan Medical School Ann Arbor MI USA M J Levin Division of Infectious Diseases Children’s Hospital Colorado and University of Colorado School of Medicine Aurora CO USA V A Morrison Veterans Affairs Medical Center and University of Minnesota Minneapolis MN USA T Vesikari Vaccine Research Center University of Tampere Medical School Tampere FinlandThe preparation of this review was not supported by any external funding During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on this article Changes resulting from comments received were made by the author on the basis of scientific and editorial merit
Keywords: